A novel class of apical sodium--dependent bile salt transporter inhibitors: 1-(2,4-bifluorophenyl)-7-dialkylamino-1,8-naphthyridine-3-carboxamides.
10.1016/j.apsb.2016.11.005
- Author:
Hongtao LIU
1
,
2
;
Guoxun PANG
3
;
Jinfeng REN
4
;
Yue ZHAO
4
;
Juxian WANG
4
Author Information
1. Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050051, China
2. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
3. Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050051, China.
4. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- Keywords:
1-(2,4-Bifluorophenyl)-7-dialkylamino-1,8-naphthyridine-3-carboxamides;
ASBT inhibitors;
Bile acids;
Cholesterol-lowering drug;
NC-1
- From:
Acta Pharmaceutica Sinica B
2017;7(2):223-229
- CountryChina
- Language:English
-
Abstract:
The apical sodium--dependent bile acid transporter (ASBT) is the main transporter to promote re-absorption of bile acids from the intestinal tract into the enterohepatic circulation. Inhibition of ASBT could increase the excretion of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Therefore, ASBT is an attractive target for developing new cholesterol-lowering drugs. In this report, a series of 1-(2,4-bifluorophenyl)-7-dialkylamino-1,8-naphthyridine-3-carboxamides were designed as inhibitors of ASBT. Most of them demonstrated potency against ASBT transport of bile acids. In particular, compoundwas found to have the best activity, resulting in 80.1% inhibition of ASBT at 10 μmol/L.
